Evidence map›Paper›PMID 25747663›Full record

ReviewTrends in microbiology2015

Towards an HIV-1 cure: measuring the latent reservoir.

Katherine M Bruner, Nina N Hosmane, Robert F Siliciano

Abstract readReview
In one paragraph

Review in Trends in microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 139 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
139citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

139 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Trial
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. TheInternational journal of molecular sciences · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. HIV Reservoir: How to Measure It?Current HIV/AIDS reports · 2023
    Review
  17. Review
  18. Article
  19. Review
  20. Article

79 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Katherine M BrunerDepartment of Medicine, Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, USA.
Nina N HosmaneDepartment of Medicine, Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, USA.
Robert F SilicianoDepartment of Medicine, Johns Hopkins University School of Medicine, 733 North Broadway, Baltimore, MD 21205, USA; Howard Hughes Medical Institute, 733 North Broadway, Baltimore, MD 21205, USA. Electronic address: rsiliciano@jhmi.edu.

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Richard E. Chaisson · 2012 to 2026
$67.0M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2M
Using NK Cells to eliminate the latent HIV reservoirU19AI096113 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LUCIW, PAUL · 2011 to 2015
$39.5M
Viral reservoirs and sanctuaries in HAART - treated patients: role and mechanismsU19AI096109 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SCHACKER, TIMOTHY W · 2011 to 2015
$29.5M
Training Program in Cellular and Molecular MedicineT32GM008752 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI RAO, RAJINI · 2000 to 2019
$11.7M
LATENT VIRAL RESERVOIRS IN HIV1 INFECTIONR01AI043222 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SILICIANO, ROBERT F · 1998 to 2013
$3.5M
SIGNIFICANCE OF LOW LEVEL VIREMIA IN PATIENTS ON HAARTR01AI051178 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SILICIANO, ROBERT F · 2002 to 2006
$1.8M
Howard Hughes Medical InstituteNIAID NIH HHS 1U19AI096109NIAID NIH HHS AI096113NIAID NIH HHS P30 AI094189NIAID NIH HHS P30AI094189NIAID NIH HHS R01 AI043222NIAID NIH HHS R01 AI051178NIAID NIH HHS U19 AI096109NIAID NIH HHS U19 AI096113NIGMS NIH HHS T32 GM007309NIGMS NIH HHS T32 GM008752PHS HHS 43222
6 · The paper itself

Abstract

The latent reservoir (LR) of HIV-1 in resting memory CD4(+) T cells serves as a major barrier to curing HIV-1 infection. While many PCR- and culture-based assays have been used to measure the size of the LR, correlation between results of different assays is poor and recent studies indicate that no available assay provides an accurate measurement of reservoir size. The discrepancies between assays are a hurdle to clinical trials that aim to measure the efficacy of HIV-1 eradication strategies. Here we describe the advantages and disadvantages of various approaches to measuring the LR.

Indexed as

Viral LoadVirus LatencyCD4-Positive T-LymphocytesDisease ReservoirsHIV-1HIV InfectionsHumansLymphocyte ActivationPolymerase Chain ReactionProvirusesT-Lymphocyte SubsetsassayscureHIV-1latency

Identifiers

PMID25747663
PMCPMC4386620

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.